Reference : A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial ...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Oncology
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
Scagliotti, G. V. [> > > >]
Smit, E. [> > > >]
Bosquee, Léon mailto [Centre Hospitalier Universitaire de Liège - CHU > > Pneumologie-Allergologie >]
O'Brien, M. [> > > >]
Ardizzoni, A. [> > > >]
Zatloukal, P. [> > > >]
Eberhardt, W. [> > > >]
Smid-Geirnaerdt, M. [> > > >]
de Bruin, H. G. [> > > >]
Dussenne, S. [> > > >]
Legrand, Catherine [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Giaccone, G. [> > > >]
Lung Cancer
Elsevier Ireland Ltd
Yes (verified by ORBi)
[en] non-small-cell lung cancer
[en] Purpose: The incidence of bronchioloalveolar carcinoma (BAC) has risen steadily over the last decades along with the increasing frequency of adenocarcinomas. BAC is relatively resistant to commonly used chemotherapy regimens. A phase 11 study with single agent pactitaxel in patients with stages IIIB, IV or recurrent BAC was performed. Experimental design: Patients with BAC with at least one target bidimensionally measurable lesion staged as unresectable stages IIIB, IV or recurrent disease, not previously irradiated; ECOG performance status 0-2; life expectancy greater than 3 months; age range between 18 and 75, received pactitaxel at a dose of 200 mg/m(2) i.v. as 3 h continuous infusion on day 1 every 21 days. Treatment was continued until progression or up to a maximum of six cycles. Results: Nineteen patients were eligible. Median number of cycles was 3 (range 0-6); 35% of patients received the planned six cycles of chemotherapy. One patient died of unrelated cause before the start of treatment. Both hematological and non-hematological toxicities were generally mild. Only one partial response (PR) was observed among the 18 eligible patients who started protocol treatment, with a response rate of 5.6% (95% Cl: 0.1-27.3%). After an independent review, two PR were confirmed, for a response rate of 11.1% (95% CI: 1.4-34.7%); nine patients had stable disease (50.0%), three patients had progressive disease (11.1%) and four patients were not assessable (22.2%). Median survival was 8.6 months (95% CI: 5.8-14.5) and 1-year survival was 35.0% (95% CI: 14.1-55.8). Median progression free survival for all patients was 2.2 months (95% CI: 1.5-6.0). The study was terminated due to the low response rate. Conclusions: Pactitaxel as single agent in stages IIIB-IV BAC was well tolerated and manageable but of limited efficacy. BAC should not be excluded from trials of new forms of chemotherapy. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Open access
A phase II study of paclitaxel in advanced.pdfAuthor postprint62.57 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.